SOX2 and ovarian cancer: These findings are supported by TCGA data showing that ovarian cancer cases classified as recurrent (n = 96) had significant enrichment of SOX2, but not OCT4 or NANOG, relative to disease-free cases (n = 41) (Figure 7A–C) [24,25,36].